This week we look at how the Covid-19 pandemic upended the proportion between the for-profit lab and imaging sectors in six of West Europe's six big markets.
While sales and profits at Europe's largest traditional players swelled during the pandemic, the sector also saw an influx of non-traditional players. The trend has seen biotech companies start to sell their COVID-19 tests direct to the customer.
Brazilian hospital group Rede D'Or has pulled back on its attempt to takeover imaging group Alliar after it became clear it could not take control. However, large lab group Fleury has now also thrown its hat into the ring for a stake.
As Europe's largest lab groups push to hoover up smaller rivals, HBI lists which mid-range assets are still up for consolidation in three major markets.
German lab group amedes is selling to a consortium including Canada's OMERS Infrastructure, Goldman Sachs Asset Management, and asset manager AXA Investment Managers.
HBI’s inaugural HBI Health Care Services Top 100 lists the largest 100 companies by EMEA health care services revenue. In total revenue their revenue came to over €105bn - and we've uncovered some surprising winners and losers.
Volumes for Romania's private hospitals are expected to jump after a law allowing inpatients to top up state tariffs with a co-payment came into force.
Governments across Europe are slashing prices and volumes of coronavirus testing in a bid to curb one of the biggest health spends of the pandemic. Many are trying to push the costs of preventive tests back onto the consumer.
Healthcare Business International users cookies to improve the functionality, performance, and effectiveness of our communications. Detailed information on the use of cookies is provided in our Cookies Policy. By continuing to use this site, or by clicking "I agree" you consent to the use of cookies.
